Cingulate Inc. (CING) |
|
0.9505 -0.03 (-3.02%)
|
01-27 15:50 |
|
Open: |
1.01 |
Pre. Close: |
0.9801 |
|
High:
|
1.03 |
Low:
|
0.9505 |
|
Volume:
|
11,488 |
Market Cap:
|
11(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:43:22 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 1.31 One year: 1.54 |
| Support: |
Support1: 0.95 Support2: 0.85 |
| Resistance: |
Resistance1: 1.12 Resistance2: 1.31 |
| Pivot: |
0.97  |
| Moving Average: |
MA(5): 1 MA(20): 0.99
MA(100): 1.06 MA(250): 1.32 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 42 %D(3): 42 |
| RSI: |
RSI(14): 54.6 |
| 52-week: |
High: 2.2 Low: 0.66 |
| Average Vol(K): |
3-Month: 53 (K) 10-Days: 29 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CING ] has closed below upper band by 18.7%. Bollinger Bands are 61% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 30 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.03 - 1.04 |
1.04 - 1.04 |
|
Low:
|
0.94 - 0.94 |
0.94 - 0.95 |
|
Close:
|
1.01 - 1.02 |
1.02 - 1.03 |
|
Company Description |
|
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas. |
Headline News |
Thu, 26 Jan 2023
Grenoble walnut PDO at Fruit Logistica for the first time - FreshPlaza.com
Tue, 24 Jan 2023
Music & Radio Station News - All Access Music Group
Wed, 11 Jan 2023
Newcastle 2-0 Leicester - Match Report: Dan-cing into the semi-final - Coming Home Newcastle
Mon, 09 Jan 2023
“Green light in production but consumption needs to pick up” - FreshPlaza.com
Wed, 04 Jan 2023
Cingulate Kickstarts First Phase 3 Trial For ADHD Candidate, Data Expected In First Half 2023 - Yahoo Finance
Fri, 16 Dec 2022
CING honours Eurobank Cyprus for CSMM support - Cyprus Mail
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
11 (M) |
| Shares Float |
9 (M) |
|
% Held by Insiders
|
27.6 (%) |
|
% Held by Institutions
|
2.3 (%) |
|
Shares Short
|
106 (K) |
|
Shares Short P.Month
|
38 (K) |
Stock Financials |
|
EPS
|
-2.16 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.74 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-145.1 |
|
Return on Equity (ttm)
|
-274.8 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-0.75 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-2.47 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-16 (M) |
|
Levered Free Cash Flow
|
-19 (M) |
Stock Valuations |
|
PE Ratio
|
-0.48 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
1.37 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.71 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
